Pevonedistat is a pyrrolopyrimidine, specifically a 7H-pyrrolo[2,3-d]pyrimidine substituted at position 4 with a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group and at position 7 with a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes. It functions as an apoptosis inducer and antineoplastic agent. It is also a secondary amino compound, a member of cyclopentanols, a sulfamidate, and a member of indanes.
